Trial purpose
Cancer treatment
Tumor type
Multi-Cancer
Age
18+
Clinical summary
Summary
This is an Early Phase 1a/1b dose-escalation and dose-expansion study with one experimental arm. In the dose escalation phase, participants will receive AK127 using the 3+3+3 model given with a fixed regimen of AK104. Both AK127 and AK104 will be administered via intravenous infusion. The dose expansion phase will open at the discretion of the Sponsor.
Conditions
This trial is treating people with advanced or metastatic solid cancers
Eligibility
Inclusion
- Written and signed informed consent
- In Phase 1a, patients with relapsed or refractory advanced solid malignancies
- In Phase 1b, patients must have received no more than three prior lines of systemic therapy
- Subject must have at least one measurable lesion according to RECIST Version1.1.
- Eastern Cooperative Oncology Group (ECOG) Performance Score of 0 or 1.
- Available archived or fresh tumor tissue
- Adequate organ function.
- For dose-expansion cohorts (Phase 1b), subjects must be willing to provide two fresh biopsy samples (pre-treatment and on treatment), where clinically appropriate.
- Females of childbearing potential and non-sterilized males who are sexually active must use an effective method of contraception from screening until 120 days after final dose of investigational product.
Exclusion
- History of severe hypersensitivity reactions to other mAbs.
- Subjects with a condition requiring systemic treatment with either corticosteroid (> 10 mg daily ) or other immunosuppressive medications within 2 weeks of study drug administration.
- Prior use of approved or investigational anti-TIGIT, anti-PVRIG, or anti-CD96 therapy
- Receiving any Other anticancer therapy (e.g., chemotherapy, radiotherapy, biologic or hormonal therapy for cancer treatment. etc.) within 4 weeks prior to the first dose of treatment
- Any major surgery within 4 weeks prior to the first dose of treatment
- Receiving agents with immunomodulatory effect within 2 weeks prior to the first dose of treatment.
- Active or prior documented inflammatory bowel disease
- History of organ transplant.
- History of interstitial lung disease, noninfectious pneumonitis except for those induced by radiation therapies.
- Known active hepatitis B or C infections or history of HIV.
- Receipt of live attenuated vaccines within 4 weeks prior to the first dose of investigational product.
- Patients with severe heart and lung dysfunction.
Inclusion
- Your cancer has spread to other parts of the body (metastatic) or has grown into nearby parts of the body (locally advanced).
- Your cancer has not spread to other parts of the body (localised).
Exclusion
- You have certain types of non-cancer medical conditions.
- You have had certain treatments, surgical procedures or drugs.
Clinical trials have complex eligibility criteria, and other criteria may apply for this trial. Ask your doctor about whether this trial could be right for you.
More information
Trial Identifiers
Information on this page is partially produced from ClinicalTrials.gov *. View further details about this trial on the registry via the links below:
Trial sponsor
Akeso
Scientific Title
A Phase 1a/1b, Multicenter, Open-Label, Dose-Escalation and Dose-Expansion Study to Evaluate the Safety, Pharmacokinetics, and Anti-tumour Activity of AK127 in Combination With AK104 in Subjects With Advanced or Metastatic Solid Tumours
Get Support
You might find it helpful to speak to someone who has 'been there before'. Our Peer Connect program can provide one-on-one phone support from someone who understands what you're going through and has clinical trials experience.
Know more about Peer Connect
If you need cancer information and practical support for yourself, a carer, family or friend, contact Cancer Council to speak with an experienced health professional on 13 11 20.
Get support
Learn more about clinical trials through this collection of resources in languages other than English.
View information